Primo Biotechnology

Executive Summary

Primo Biotechnology is a Taiwanese radiopharmaceutical company focused on precision oncology, leveraging its proprietary linker library and automated synthesis platforms to develop targeted radioligand theranostics using isotopes such as Lu-177 and Tb-161. Founded in 2021, the company operates a GMP-compliant manufacturing facility and is currently advancing its pipeline into Phase 1 clinical trials. With a strong emphasis on both diagnostic imaging and targeted therapy, Primo’s approach aims to improve treatment specificity and patient outcomes in cancer care. The company’s early-stage status and niche focus on emerging radionuclides like Tb-161 position it as a potential player in the growing radiopharmaceutical market, though it faces competition from larger established firms. Given the lack of publicly disclosed clinical data, the near-term prospects hinge on successful trial initiation and potential strategic partnerships to validate its technology platform.

Upcoming Catalysts (preview)

• Q3 2026Initiation of First Phase 1 Trial70% success
• Q4 2026Strategic Partnership or Licensing Deal40% success
• Q2 2026Series A or B Funding Round60% success